EUVIMEDTutustu EUVIMEDiin
Open access · CC BY 4.0

Risk Factors of Reactive Cutaneous Capillary Endothelial Proliferation in Advanced Non-small Cell Lung Cancer Treated with Camrelizumab

Liuning Wang, Shuxing Chen, Siyu Sun, Wenyi Li, Congjun Zhang

Life Conflux · 2026-03-06 · 2 (2) · e350

DOI: 10.71321/ncbcdv45 ↗

At a glance

Journal article in Life Conflux, published online on 2026-03-06. Written by Liuning Wang and 4 co-authors. 34 references. The full text is freely available (open access, CC BY 4.0).

TiivistelmäBibliografiset tiedotCiteRelated studies

Abstract (original language)

Background

Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common cutaneous immune-related adverse event (irAE) of camrelizumab. The purpose of our research was to explore the risk factors associated with RCCEP and their predictive values.

Methods

We conducted a retrospective investigation examining clinical records of advanced non-small cell lung cancer (NSCLC) patients treated with camrelizumab at our hospital between June 2022 and December 2024. Study participants were grouped based on whether they developed RCCEP. To pinpoint potential risk factors associated with RCCEP, we employed logistic regression analysis, while receiver operating characteristic (ROC) curve analysis helped determine the predictive values of our identified variables.

Results

Among 194 patients, 94 (48.5%) developed RCCEP, of whom 92 cases developed grade 1-2 RCCEP, only 2 cases developed grade 3 RCCEP, with no grade 4-5 cases. Multivariate logistic regression analysis suggested that not using combined anti-angiogenic drugs (OR: 2.962, 95% CI 1.042-8.422, P = 0.042), high baseline albumin level (OR: 1.422, 95% CI 1.264-1.599, P < 0.001), and high baseline platelet count (OR: 1.018, 95% CI 1.010-1.026, P < 0.001) were significantly associated with RCCEP. ROC curve analysis showed that baseline albumin level, baseline platelet count, and their combination predicted RCCEP occurrence in advanced NSCLC patients receiving camrelizumab, with areas under the curve (AUCs) of 0.836 (95% CI 0.777-0.895), 0.778 (95% CI 0.709-0.847), and 0.874 (95% CI 0.823-0.924), respectively. The cutoff values for albumin and platelet were calculated using the maximum Youden index from the ROC curve, which were 36.85 g/L and 225×109/L, respectively.

Conclusion

Not using combined anti-angiogenic drugs, high baseline albumin level, and high baseline platelet count were independent risk factors of camrelizumab-related RCCEP, and the combined indicator had higher predictive value. We recommend increasing clinical attention and personalizing management for patients with the above risk factors for RCCEP to improve patient compliance and achieve long-term treatment outcomes.

Cite

APA

Wang, L., Chen, S., Sun, S., Li, W., & Zhang, C. (2026). Risk Factors of Reactive Cutaneous Capillary Endothelial Proliferation in Advanced Non-small Cell Lung Cancer Treated with Camrelizumab. Life Conflux, 2(2), e350. https://doi.org/10.71321/ncbcdv45

Vancouver

Wang L, Chen S, Sun S, Li W, Zhang C. Risk Factors of Reactive Cutaneous Capillary Endothelial Proliferation in Advanced Non-small Cell Lung Cancer Treated with Camrelizumab. Life Conflux. 2026;2(2):e350. doi:10.71321/ncbcdv45

BibTeX
@article{Wang2026,
  author = {Wang, Liuning and Chen, Shuxing and Sun, Siyu and Li, Wenyi and Zhang, Congjun},
  title = {Risk Factors of Reactive Cutaneous Capillary Endothelial Proliferation in Advanced Non-small Cell Lung Cancer Treated with Camrelizumab},
  journal = {Life Conflux},
  year = {2026},
  volume = {2},
  number = {2},
  pages = {e350},
  doi = {10.71321/ncbcdv45}
}
Start for free →